OC
MCID: OVR042
MIFTS: 89

Ovarian Cancer (OC)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Ovarian Cancer

MalaCards integrated aliases for Ovarian Cancer:

Name: Ovarian Cancer 57 11 19 42 58 75 73 28 12 53 5 41 2 14 33
Ovarian Carcinoma 11 19 42 53 5 14 16 71
Ovarian Neoplasm 11 16 71
Primary Malignant Neoplasm of Ovary 71 33
Malignant Neoplasm of Ovary 71 31
Malignant Tumour of Ovary 11 33
Epithelial Ovarian Cancer 73 71
Cancer of the Ovary 42 75
Neoplasm of Ovary 28 5
Ovarian Neoplasms 53 43
Ovarian Cancers 5 14
Malignant Neoplasm of the Ovary 42
Malignant Tumor of the Ovary 42
Ovarian Cancer, Somatic 57
Malignant Ovarian Tumor 11
Ovarian Malignant Tumor 58
Primary Ovarian Cancer 11
Tumor of the Ovary 11
Ovarian Carcinomas 14
Cancer, Ovarian 38
Cancer of Ovary 33
Ovary Neoplasm 11
Ovary Cancer 33
Ca Ovary 33
Oc 73

Characteristics:


Inheritance:

Somatic mutation 57

Prevelance:

1-5/10000 (Europe) 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:2394 DOID:4001
OMIM® 57 167000
ICD9CM 34 183.0
MeSH 43 D010051
NCIt 49 C4984 C7431
ICD10 31 C56
UMLS via Orphanet 72 C1140680
Orphanet 58 ORPHA213500
SNOMED-CT via HPO 69 254838004 60718004
UMLS 71 C0029925 C0677886 C0919267 more

Summaries for Ovarian Cancer

MedlinePlus: 41 What is ovarian cancer? Cancer is a disease in which abnormal cells in the body grow out of control and form a tumor. Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones. What are the types of ovarian cancer? There are a few different types of ovarian cancer. The most common type is epithelial cancer. It begins in the cells that cover the ovary. There are also two related types of epithelial cancer that can spread to the ovaries: Fallopian tube cancer forms in the tissue lining a fallopian tube. The fallopian tubes are a pair of long, slender tubes on each side of the uterus. The uterus is the female reproductive organ where a baby grows during pregnancy. Primary peritoneal cancer forms in the tissue lining the peritoneum. Your peritoneum is a tissue lining that covers the organs in the abdomen (belly). These two cancers are similar to ovarian cancer, and they have the same treatments. So some medical experts also consider those two types as ovarian cancer. Some other rarer types of ovarian cancer are malignant germ cell tumors and stromal tumors. What causes ovarian cancer? Ovarian cancer happens when there are changes (mutations) in the genetic material (DNA). Often, the exact cause of these genetic changes is unknown. Most ovarian cancers are caused by genetic changes that happen during your lifetime. But sometimes these genetic changes are inherited, meaning that you are born with them. Ovarian cancer that is caused by inherited genetic changes is called hereditary ovarian cancer. There are also certain genetic changes that can raise your risk of ovarian cancer, including changes called BRCA1 and BRCA2. These two changes also raise your risk of breast and other cancers. Besides genetics, your lifestyle and the environment can affect your risk of ovarian cancer. Who is more likely to develop ovarian cancer? Certain people are more likely to develop ovarian cancer. They include those who: Have a family history of ovarian cancer in a mother, daughter, or sister Have inherited changes in the BRCA1 or BRCA2 genes. Have certain other genetic conditions, such as Lynch syndrome Have endometriosis Took hormone replacement therapy Are overweight or have obesity Are tall Are older, especially those who have gone through menopause What are the symptoms of ovarian cancer? Ovarian cancer may not cause early signs or symptoms. By the time you do have signs or symptoms, the cancer is often advanced. The signs and symptoms may include: Pain, swelling, or a feeling of pressure in the abdomen or pelvis Sudden or frequent urge to urinate (pee) Trouble eating or feeling full A lump in the pelvic area Gastrointestinal problems, such as gas, bloating, or constipation How is ovarian cancer diagnosed? To find out if you have ovarian cancer, your health care provider: Will ask about your medical history, including your symptoms Will ask about your family health history, including relatives who have had ovarian cancer Will do a physical exam, including a pelvic exam Will likely do imaging tests May do blood tests such as a CA-125 blood test Often the only way to know for sure that you have ovarian cancer is by having a biopsy of the tissue. A biopsy is done during surgery to remove the tumor. What are the treatments for ovarian cancer? Treatments for ovarian cancer may include: Surgery to remove as much of the cancer as possible Chemotherapy Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells Your provider may suggest that you have genetic testing to look for the gene changes that raise the risk for ovarian cancer. Knowing whether or not you have the gene change may help your provider decide on your treatment plan. NIH: National Cancer Institute

MalaCards based summary: Ovarian Cancer, also known as ovarian carcinoma, is related to hereditary breast ovarian cancer syndrome and breast cancer, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Fosaprepitant and Tranexamic acid have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and uterus, and related phenotypes are breast carcinoma and dysgerminoma

MedlinePlus Genetics: 42 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.The most common form of ovarian cancer begins in epithelial cells, which are the cells that line the surfaces and cavities of the body. These cancers can arise in the epithelial cells on the surface of the ovary. However, researchers suggest that many or even most ovarian cancers begin in epithelial cells on the fringes (fimbriae) at the end of one of the fallopian tubes, and the cancerous cells migrate to the ovary.Cancer can also begin in epithelial cells that form the lining of the abdomen (the peritoneum). This form of cancer, called primary peritoneal cancer, resembles epithelial ovarian cancer in its origin, symptoms, progression, and treatment. Primary peritoneal cancer often spreads to the ovaries. It can also occur even if the ovaries have been removed. Because cancers that begin in the ovaries, fallopian tubes, and peritoneum are so similar and spread easily from one of these structures to the others, they are often difficult to distinguish. These cancers are so closely related that they are generally considered collectively by experts.In about 10 percent of cases, ovarian cancer develops not in epithelial cells but in germ cells, which are precursors to egg cells, or in hormone-producing ovarian cells called granulosa cells.In its early stages, ovarian cancer usually does not cause noticeable symptoms. As the cancer progresses, signs and symptoms can include pain or a feeling of heaviness in the pelvis or lower abdomen, bloating, feeling full quickly when eating, back pain, vaginal bleeding between menstrual periods or after menopause, or changes in urinary or bowel habits. However, these changes can occur as part of many different conditions. Having one or more of these symptoms does not mean that a woman has ovarian cancer.In some cases, cancerous tumors can invade surrounding tissue and spread to other parts of the body. If ovarian cancer spreads, cancerous tumors most often appear in the abdominal cavity or on the surfaces of nearby organs such as the bladder or colon. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers.Some ovarian cancers cluster in families. These cancers are described as hereditary and are associated with inherited gene mutations. Hereditary ovarian cancers tend to develop earlier in life than non-inherited (sporadic) cases.Because it is often diagnosed at a late stage, ovarian cancer can be difficult to treat; it leads to the deaths of about 14,000 women annually in the United States, more than any other gynecological cancer. However, when it is diagnosed and treated early, the 5-year survival rate is high.

CDC: 2 Cancer is a disease in which abnormal cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. Ovarian cancer is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Women have two ovaries that are located in the pelvis, one on each side of the uterus. The ovaries make female hormones and produce eggs. Women have two fallopian tubes that are a pair of long, slender tubes on each side of the uterus. Eggs pass from the ovaries through the fallopian tubes to the uterus. The peritoneum is the tissue lining that covers organs in the abdomen. When ovarian cancer is found in its early stages, treatment works best. Ovarian cancer often causes signs and symptoms, so it is important to pay attention to your body and know what is normal for you. Symptoms may be caused by something other than cancer, but the only way to know is to see your doctor, nurse, or other health care professional. Some mutations (changes in genes) can raise your risk for ovarian cancer. Mutations in the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2), and those associated with Lynch syndrome, raise ovarian cancer risk. Ovarian cancers come in a variety of different tumor types. The most common tumor type is high-grade serous carcinoma, occurring in about 70% of ovarian cancer cases.

GARD: 19 Ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. Many people with early Ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Most cases of Ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of Ovarian cancers are thought to be "hereditary." Although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as BRCA1 or BRCA2 hereditary breast and Ovarian cancer syndrome, Lynch syndrome and Peutz-Jeghers syndrome) and are inherited in an autosomal dominant manner.

OMIM®: 57 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases (Chi et al., 2001). These typical features relate to the biology of the disease, which is a principal determinant of outcome (Auersperg et al., 2001). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium (Stany et al., 2008; Soslow, 2008). (167000) (Updated 24-Oct-2022)

UniProtKB/Swiss-Prot: 73 The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Novus Biologicals: 54 Tumor markers can be found in the body when cancer is present. They are most often found in the blood or urine, but can also be found in tumors and other tissues. High level of the tumor marker CA125 in the blood strongly suggests ovarian cancer. CA125 is an antigen present on 80% of non-mucinous ovarian carcinomas.

Disease Ontology 11 Ovarian cancer: A female reproductive organ cancer that is located in the ovary.

Ovarian carcinoma: An ovarian cancer that has material basis in epithelial tissue and is located in the ovary.

Wikipedia: 75 Ovarian cancer is a cancerous tumor of an ovary. It may originate from the ovary itself or more commonly... more...

Related Diseases for Ovarian Cancer

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Familial Ovarian Cancer

Diseases related to Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1758)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 35.1 TP53 RAD51D RAD51C PTEN PIK3CA MSH6
2 breast cancer 35.0 TP53 RAD51D RAD51C PTEN PIK3CA MSH6
3 ovarian cancer 1 34.5 RAD51C BRIP1 BRCA2 BRCA1
4 serous cystadenocarcinoma 34.3 TP53 RAD51D RAD51C PTEN PIK3CA MSH6
5 lynch syndrome 34.1 TP53 RAD51D RAD51C PTEN PIK3CA MSH6
6 breast-ovarian cancer, familial 1 34.0 RAD51C BRIP1 BRCA2 BRCA1
7 endometrial cancer 34.0 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
8 hereditary site-specific ovarian cancer syndrome 33.7 RAD51D RAD51C BRCA2 BRCA1
9 adenocarcinoma 33.7 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
10 bap1 tumor predisposition syndrome 33.7 TP53 RAD51D RAD51C PTEN MSH6 MSH2
11 inherited cancer-predisposing syndrome 33.7 TP53 RAD51D RAD51C PTEN MSH6 MSH2
12 ovary adenocarcinoma 33.6 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
13 ovarian disease 33.5 TP53 PTEN ERBB2 CTNNB1 BRCA2 BRCA1
14 pancreatic cancer 33.4 TP53 PTEN PIK3CA MSH6 MSH2 MAP3K1
15 colorectal cancer 33.4 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
16 breast-ovarian cancer, familial 2 33.3 BRCA2 BRCA1
17 ovarian clear cell carcinoma 33.3 TP53 PTEN PIK3CA KRAS BRCA1 AKT1
18 ovary epithelial cancer 33.3 TP53 PTEN KRAS ERBB2 CDH1 BRCA2
19 fallopian tube carcinoma 33.2 TP53 RAD51D RAD51C PTEN MSH6 MSH2
20 peripheral nervous system disease 33.2 TP53 PTEN PRKN KRAS ERBB2 CTNNB1
21 lung cancer 33.2 TP53 PTEN PRKN PIK3CA MSH2 KRAS
22 ovarian serous cystadenocarcinoma 33.1 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
23 prostate cancer 33.1 TP53 RAD51D PTEN PIK3CA MSH6 MSH2
24 li-fraumeni syndrome 33.1 TP53 RAD51D RAD51C PTEN PIK3CA MSH6
25 familial ovarian cancer 33.1 TP53 RAD51C
26 ovarian cystadenocarcinoma 33.0 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
27 fanconi anemia, complementation group a 33.0 TP53 RAD51D RAD51C PTEN PRKN MSH6
28 cystadenocarcinoma 32.9 TP53 PTEN KRAS BRCA2 BRCA1 AKT1
29 colonic benign neoplasm 32.9 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
30 leukemia, acute myeloid 32.8 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
31 gastric cancer 32.8 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
32 wilms tumor 1 32.8 TP53 PTEN KRAS ERBB2 CTNNB1 CDKN2A
33 bladder cancer 32.8 TP53 PTEN PIK3CA MSH2 KRAS ERBB2
34 glioblastoma 32.7 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
35 melanoma 32.7 TP53 PTEN PIK3CA KRAS CTNNB1 CDKN2A
36 carcinosarcoma 32.7 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
37 adenoma 32.7 TP53 PIK3CA MSH6 MSH2 KRAS CTNNB1
38 mucinous adenocarcinoma 32.7 TP53 PIK3CA MSH6 MSH2 KRAS ERBB2
39 in situ carcinoma 32.7 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
40 cowden syndrome 32.6 TP53 RAD51D RAD51C PTEN PIK3CA MSH6
41 renal cell carcinoma, nonpapillary 32.6 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
42 bilateral breast cancer 32.6 TP53 RAD51D RAD51C PTEN ERBB2 CDKN2A
43 lung cancer susceptibility 3 32.6 TP53 PRKN PIK3CA KRAS ERBB2 CTNNB1
44 uterine corpus cancer 32.6 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
45 hepatocellular carcinoma 32.6 TP53 PTEN PIK3CA MSH2 KRAS ERBB2
46 appendix adenocarcinoma 32.6 TP53 MSH6 KRAS
47 lynch syndrome i 32.5 RAD51D MSH6 MSH2 BRCA2 BRCA1
48 teratoma 32.5 TP53 PTEN KRAS ERBB2 CTNNB1 CDKN2A
49 cervical cancer 32.5 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDKN2A
50 diffuse gastric and lobular breast cancer syndrome 32.4 TP53 RAD51D RAD51C PTEN PIK3CA MSH6

Comorbidity relations with Ovarian Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Fallopian Tube Carcinoma Hydronephrosis
Intestinal Obstruction Myofibroma
Neutropenia Paralytic Ileus
Peritoneum Cancer Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ovarian Cancer:



Diseases related to Ovarian Cancer

Symptoms & Phenotypes for Ovarian Cancer

Human phenotypes related to Ovarian Cancer:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 breast carcinoma 30 HP:0003002
2 dysgerminoma 30 HP:0100621
3 ovarian papillary adenocarcinoma 30 HP:0006774

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Neoplasia:
dysgerminoma
ovarian papillary adenocarcinoma
breast cancer
ovarian cancer
serous ovarian cystadenocarcinoma

Laboratory Abnormalities:
frequent loss of heterozygosity at 6q24-q27

Clinical features from OMIM®:

167000 (Updated 24-Oct-2022)

UMLS symptoms related to Ovarian Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer according to GeneCards Suite gene sharing:

25 (show all 32)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.17 KRAS PIK3CA BRAF
2 Decreased viability GR00055-A-2 11.17 KRAS PIK3CA BRAF
3 Decreased viability GR00055-A-3 11.17 KRAS
4 Decreased viability GR00106-A-0 11.17 KRAS
5 Decreased viability GR00107-A-1 11.17 MAP3K1
6 Decreased viability GR00221-A-1 11.17 AKT1 KRAS PIK3CA CDH1 CDKN2A
7 Decreased viability GR00221-A-2 11.17 AKT1 BRCA1 KRAS MAP3K1 PIK3CA
8 Decreased viability GR00221-A-3 11.17 AKT1 BRCA1 MAP3K1 CDKN2A ERBB2
9 Decreased viability GR00221-A-4 11.17 AKT1 PIK3CA CDKN2A BRAF ERBB2
10 Decreased viability GR00249-S 11.17 AKT1 BRAF
11 Decreased viability GR00301-A 11.17 BRCA1 KRAS CDH1 BRAF MSH2
12 Decreased viability GR00381-A-1 11.17 KRAS BRAF
13 Decreased viability GR00402-S-2 11.17 PIK3CA CDH1
14 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.34 AKT1 BRCA1 BRCA2 CDKN2A PTEN
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.34 AKT1 BRCA1 BRCA2 CDKN2A PRKN PTEN
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 10.34 BRCA1 BRCA2 RAD51D TP53 MSH2 MSH6
17 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.93 BRAF BRCA1 BRCA2 MAP3K1 MSH2 RAD51D
18 Increased cell migration GR00055-A-1 9.71 CTNNB1
19 Increased cell migration GR00055-A-3 9.71 CTNNB1
20 Synthetic lethal with cisplatin GR00101-A-1 9.54 BRCA1 BRCA2 BRIP1
21 Decreased viability with cisplatin GR00101-A-4 9.5 BRCA1 BRCA2 BRIP1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.36 KRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.36 BRAF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.36 AKT1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.36 KRAS
26 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.36 BRAF CTNNB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.36 AKT1 PIK3CA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.36 KRAS
29 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.36 AKT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.36 AKT1
31 Increased cell death in HCT116 cells GR00103-A-0 9.26 CTNNB1 PIK3CA
32 Decreased viability in pancreas lineage GR00235-A 8.85 TP53

MGI Mouse Phenotypes related to Ovarian Cancer:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.51 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
2 homeostasis/metabolism MP:0005376 10.5 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
3 nervous system MP:0003631 10.49 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDKN2A
4 growth/size/body region MP:0005378 10.47 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
5 cellular MP:0005384 10.43 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
6 endocrine/exocrine gland MP:0005379 10.37 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
7 embryo MP:0005380 10.36 AKT1 BRAF BRCA1 BRCA2 CDH1 CDKN2A
8 muscle MP:0005369 10.35 AKT1 BRAF BRCA1 CDKN2A CTNNB1 ERBB2
9 normal MP:0002873 10.34 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
10 cardiovascular system MP:0005385 10.33 AKT1 BRAF BRCA1 CDH1 CDKN2A CTNNB1
11 behavior/neurological MP:0005386 10.28 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDKN2A
12 digestive/alimentary MP:0005381 10.27 BRAF BRCA1 BRCA2 CDH1 CDKN2A CTNNB1
13 immune system MP:0005387 10.25 AKT1 BRAF BRCA1 BRCA2 CDH1 CDKN2A
14 pigmentation MP:0001186 10.21 BRAF BRCA1 CDKN2A CTNNB1 KRAS MAP3K1
15 limbs/digits/tail MP:0005371 10.21 BRAF BRCA1 BRCA2 CTNNB1 ERBB2 KRAS
16 no phenotypic analysis MP:0003012 10.19 CDH1 CDKN2A CTNNB1 KRAS OPCML PIK3CA
17 liver/biliary system MP:0005370 10.17 AKT1 BRAF BRIP1 CDKN2A CTNNB1 KRAS
18 reproductive system MP:0005389 10.17 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
19 respiratory system MP:0005388 10.07 AKT1 BRAF BRCA1 CDKN2A CTNNB1 ERBB2
20 skeleton MP:0005390 10.07 AKT1 BRAF BRCA1 BRCA2 CDKN2A CTNNB1
21 hematopoietic system MP:0005397 10 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDKN2A
22 mortality/aging MP:0010768 9.91 AKT1 BRAF BRCA1 BRCA2 CDH1 CDKN2A
23 integument MP:0010771 9.53 AKT1 BRAF BRCA1 BRCA2 CDH1 CDKN2A

Drugs & Therapeutics for Ovarian Cancer

Drugs for Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 631)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fosaprepitant Approved Phase 4 172673-20-0 219090 135413538
2
Tranexamic acid Approved Phase 4 1197-18-8 5526
3
Ferrous fumarate Approved Phase 4 141-01-5
4
Metronidazole Approved Phase 4 443-48-1, 69198-10-3 4173
5
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
6
Rivoceranib Investigational Phase 4 811803-05-1 11315474
7 Gastrointestinal Agents Phase 4
8 Neurokinin-1 Receptor Antagonists Phase 4
9 Protein Kinase Inhibitors Phase 4
10
Hydralazine Approved Phase 3 86-54-4 3637
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
12
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
13
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
14
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
15
Famotidine Approved Phase 3 76824-35-6 3325 5702160
16
Cetirizine Approved Phase 3 83881-51-0 2678
17
Histamine Approved, Investigational Phase 3 51-45-6 774
18
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
19
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
20
Ofloxacin Approved Phase 3 82419-36-1 4583
21
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
22
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
23
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
24
Decitabine Approved, Investigational Phase 2, Phase 3 2353-33-5 451668
25
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
26
Etoposide Approved Phase 3 33419-42-0 36462
27
Selenium Approved, Investigational, Vet_approved Phase 3 7783-07-5, 7782-49-2 533
28
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
29
Bupivacaine Approved, Investigational Phase 3 2180-92-9, 38396-39-3 2474
30
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
31 Mango Approved Phase 3
32
Bleomycin Approved, Investigational Phase 3 9041-93-4, 11056-06-7 5360373
33
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
34
Selenious acid Approved, Investigational Phase 3 14124-67-5, 7783-00-8 1091
35
Calcium polycarbophil Approved Phase 3 126040-58-2
36
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
37
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
38
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
39
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
40
Adenosine Approved, Investigational Phase 3 58-61-7 60961
41
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
42
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
43
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
44
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2 23431961
45
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
46
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
47
Itraconazole Approved, Investigational Phase 2, Phase 3 84625-61-6 55283
48
(R)-Bicalutamide Approved, Experimental Phase 2, Phase 3 90357-06-5, 113299-40-4 2375
49
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
50
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60699 60700

Interventional clinical trials:

(show top 50) (show all 2767)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic Malignancies Unknown status NCT03858166 Phase 4 PEG-rhG-CSF
2 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
3 Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
4 Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
5 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Completed NCT04352439 Phase 4 Aspirin
6 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
7 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
8 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Completed NCT02476968 Phase 4 Olaparib
9 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Completed NCT03543462 Phase 4
10 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Completed NCT01953107 Phase 4
11 A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
12 Continuation of Treatment and Monitoring of Safety in Patients Treated With LY353381 for Advanced Cancer Completed NCT00190697 Phase 4 arzoxifene
13 A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
14 Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. Completed NCT03384511 Phase 4 Apatinib
15 Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment (300mg or 200 mg/Day) for Ovarian Cancer Patients. Recruiting NCT04861181 Phase 4
16 An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice Recruiting NCT01932125 Phase 4 Bevacizumab
17 Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer Recruiting NCT03164980 Phase 4 Trabectidin (Yondelis)
18 A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
19 Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study Active, not recruiting NCT03752216 Phase 4 Niraparib
20 A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation Active, not recruiting NCT04330040 Phase 4 Olaparib
21 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Active, not recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
22 A Phase IV Open-label, Multicenter Study of Niraparib as Maintenance Therapy in BRCA Wild-type, Newly Diagnosed Advanced Ovarian Cancer Patients in Korea Not yet recruiting NCT05187208 Phase 4 Niraparib
23 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
24 Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study. Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
25 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
26 Evaluating the Effectiveness of Inquiry Based Stress Reduction (IBSR) Intervention Versus Regular Care of no Treatment on Well-being, Optimism and Health Behavior of BRCA1/2 Carriers: A Randomized Controlled Trial, RCT. Unknown status NCT03162276 Phase 3
27 Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy. Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
28 Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel for the Treatment of Patients With Recurrent or Primary Advanced Ovarian Cancer : A Randomised Phase 3 Study Unknown status NCT02681432 Phase 3 HIPEC
29 Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC) Unknown status NCT04055038 Phase 2, Phase 3 Platinum-Based Drug;Conventional chemotherapy
30 Long-acting Versus Short-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Patients: A Multicenter Phase 3 Randomized Controlled Study Unknown status NCT04101760 Phase 3 Long-acting granulocyte colony stimulating factor;Short-acting granulocyte colony stimulating factor
31 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
32 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
33 Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer. Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
34 Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer Unknown status NCT00326456 Phase 3 liposomal doxorubicin;carboplatin;paclitaxel
35 AMELIE: A Phase 3 Randomized, Open-label, Multicenter Trial of Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant or Refractory Ovarian Cancer Unknown status NCT04000295 Phase 3 Apatinib;Etoposide;Paclitaxel
36 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
37 A Phase III Multicenter Prospective Randomized Controlled Clinical Trial of HIPEC as NACT and Postoperative Chemotherapy After Interval Debulking Surgery in the Treatment of Advanced-Stage Epithelial Ovarian Cancer Unknown status NCT03180177 Phase 3 neoadjuvant chemotherapy;adjuvant chemotherapy
38 Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial Unknown status NCT00726635 Phase 3
39 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
40 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
41 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
42 Protocol for the Treatment of Extracranial Germ Cell Tumours in Children and Adolescents (GC III) Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
43 Role of Geriatric Intervention in Treatment of Older Patients With Cancer : a Phase III Randomized Study (PREPARE) Unknown status NCT02704832 Phase 3
44 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Paclitaxel
45 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
46 Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel. Unknown status NCT01628380 Phase 3
47 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
48 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00951496 Phase 3 Carboplatin;Cisplatin;Paclitaxel
49 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
50 The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel

Search NIH Clinical Center for Ovarian Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Altretamine
Carboplatin
Chlorambucil
Chromic phosphate P32
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
docetaxel
doxorubicin hydrochloride liposome
hydroxyurea
Ifosfamide
Leuprolide
Leuprolide Acetate
Melphalan
Melphalan hydrochloride
Paclitaxel
Topotecan
Topotecan Hydrochloride
Uracil Mustard
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: ovarian neoplasms

Genetic Tests for Ovarian Cancer

Genetic tests related to Ovarian Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Ovary 28 AKT1 CDH1 CTNNB1 ERBB2 OPCML PIK3CA PRKN
2 Ovarian Cancer 28

Anatomical Context for Ovarian Cancer

Organs/tissues related to Ovarian Cancer:

FMA: Ovary, Ovary
MalaCards : Ovary, Breast, Uterus, T Cells, Colon, Lymph Node, Liver

Publications for Ovarian Cancer

Articles related to Ovarian Cancer:

(show top 50) (show all 50955)
# Title Authors PMID Year
1
Mutations in BRIP1 confer high risk of ovarian cancer. 62 57 5
21964575 2011
2
OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. 62 57 5
12819783 2003
3
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. 57 5
12719539 2003
4
Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. 53 62 57
19635727 2010
5
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. 53 62 5
19358724 2009
6
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. 53 62 5
19018267 2008
7
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 53 62 5
17611497 2007
8
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. 53 62 57
15619626 2005
9
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. 53 62 57
11179017 2001
10
The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. 53 62 57
10577927 1999
11
DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. 53 62 57
9620555 1998
12
BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. 62 5
29368626 2018
13
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. 62 5
28423363 2017
14
Inherited Mutations in Women With Ovarian Carcinoma. 62 5
26720728 2016
15
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. 62 5
26315354 2015
16
Whole-genome characterization of chemoresistant ovarian cancer. 62 57
26017449 2015
17
Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. 62 57
23467088 2013
18
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. 62 5
22271473 2012
19
Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. 62 5
21990120 2012
20
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. 62 5
22006311 2011
21
Epidermal growth factor receptor blockers for the treatment of ovarian cancer. 62 5
21975775 2011
22
RAD51C is a susceptibility gene for ovarian cancer. 62 5
21616938 2011
23
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. 62 5
21683865 2011
24
Integrated genomic analyses of ovarian carcinoma. 62 57
21720365 2011
25
MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. 53 62 46
20461750 2010
26
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. 62 57
19304784 2009
27
Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. 62 57
19270026 2009
28
Dicer, Drosha, and outcomes in patients with ovarian cancer. 62 57
19092150 2008
29
A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. 53 5
18628483 2008
30
Histologic subtypes of ovarian carcinoma: an overview. 62 57
18317227 2008
31
The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. 62 57
18026186 2008
32
Classification of ovarian cancer: a genomic analysis. 62 57
18546616 2008
33
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. 53 62 46
18199536 2008
34
Alterations in the common fragile site gene Parkin in ovarian and other cancers. 53 57
14614460 2003
35
Identification of prognostic factors in advanced epithelial ovarian carcinoma. 62 57
11520151 2001
36
Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions. 62 57
9826475 1998
37
Is hereditary site-specific ovarian cancer a distinct genetic condition? 62 57
9450858 1998
38
A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. 62 57
8603384 1996
39
Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. 62 57
8640783 1996
40
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. 53 57
7942844 1994
41
A human oncogene of the RAS superfamily unmasked by expression cDNA cloning. 62 5
8052619 1994
42
Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. 62 57
8314147 1994
43
Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers. 62 57
1394208 1992
44
Allele losses on chromosome 17 in human epithelial ovarian carcinoma. 62 57
2250917 1990
45
An oncogenic chromosome 8-9 gene fusion isolated following transfection of human ovarian carcinoma cell line DNA. 62 57
1973829 1990
46
Familial ovarian carcinoma. 62 57
4320145 1970
47
Cost Study of the PlasmaJet Surgical Device Versus Conventional Cytoreductive Surgery in Patients With Advanced-Stage Ovarian Cancer. 62 41
36198130 2022
48
Germline-Activating RRAS2 Mutations Cause Noonan Syndrome. 5
31130285 2019
49
Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome. 5
31130282 2019
50
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. 57
31043742 2019

Variations for Ovarian Cancer

ClinVar genetic disease variations for Ovarian Cancer:

5 (show top 50) (show all 683)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PRKN PARK2, DEL DEL Pathogenic
7039 GRCh37:
GRCh38:
2 OPCML NM_001012393.5(OPCML):c.263C>G (p.Pro88Arg) SNV Pathogenic
8983 rs137852691 GRCh37: 11:132527098-132527098
GRCh38: 11:132657203-132657203
3 ERBB2 NM_004448.4(ERBB2):c.2570A>G (p.Asn857Ser) SNV Pathogenic
13880 rs28933370 GRCh37: 17:37881378-37881378
GRCh38: 17:39725125-39725125
4 BRIP1 NM_032043.3(BRIP1):c.1234_1235del (p.Glu412fs) DEL Pathogenic
422238 rs1064795649 GRCh37: 17:59876566-59876567
GRCh38: 17:61799205-61799206
5 RRAS2 NM_012250.6(RRAS2):c.215A>T (p.Gln72Leu) SNV Pathogenic
9447 rs113954997 GRCh37: 11:14316390-14316390
GRCh38: 11:14294844-14294844
6 RAD51C NM_058216.3(RAD51C):c.230del (p.Gly77fs) DEL Pathogenic
31557 rs1057519355 GRCh37: 17:56772375-56772375
GRCh38: 17:58695014-58695014
7 CTNNB1 NM_001904.4(CTNNB1):c.283C>T (p.Arg95Ter) SNV Pathogenic
265443 rs775104326 GRCh37: 3:41266486-41266486
GRCh38: 3:41224995-41224995
8 TP53 NM_000546.6(TP53):c.537T>A (p.His179Gln) SNV Pathogenic
406578 rs876660821 GRCh37: 17:7578393-7578393
GRCh38: 17:7675075-7675075
9 TP53 NM_000546.6(TP53):c.438G>A (p.Trp146Ter) SNV Pathogenic
428890 rs1131691026 GRCh37: 17:7578492-7578492
GRCh38: 17:7675174-7675174
10 BRIP1 NM_032043.3(BRIP1):c.438_440delinsCT (p.Tyr147fs) INDEL Pathogenic
187045 rs786203429 GRCh37: 17:59926557-59926559
GRCh38: 17:61849196-61849198
11 TP53 NM_000546.6(TP53):c.880G>T (p.Glu294Ter) SNV Pathogenic
379471 rs1057520607 GRCh37: 17:7577058-7577058
GRCh38: 17:7673740-7673740
12 TP53 NM_000546.6(TP53):c.811G>T (p.Glu271Ter) SNV Pathogenic
1174012 GRCh37: 17:7577127-7577127
GRCh38: 17:7673809-7673809
13 ATM DEL Pathogenic
1174013 GRCh37: 11:108098332-108236255
GRCh38:
14 NBN NM_002485.5(NBN):c.1147G>T (p.Glu383Ter) SNV Pathogenic
1244220 GRCh37: 8:90967761-90967761
GRCh38: 8:89955533-89955533
15 NBN NM_002485.5(NBN):c.1071dup (p.Val358fs) DUP Pathogenic
1244221 GRCh37: 8:90971005-90971006
GRCh38: 8:89958777-89958778
16 BRCA2 NM_000059.4(BRCA2):c.4284del (p.Gln1429fs) DEL Pathogenic
560356 rs80359439 GRCh37: 13:32912776-32912776
GRCh38: 13:32338634-32338634
17 BRCA2 NM_000059.4(BRCA2):c.68-352_317-1637del DEL Pathogenic
635874 GRCh37: 13:32892842-32897556
GRCh38: 13:32318705-32323419
18 RAD51D, RAD51L3-RFFL NM_002878.4(RAD51D):c.480+1G>A SNV Pathogenic
30286 rs1597862471 GRCh37: 17:33434006-33434006
GRCh38: 17:35106987-35106987
19 CHEK2 NM_007194.4(CHEK2):c.792+2T>A SNV Pathogenic
944881 rs545982789 GRCh37: 22:29107895-29107895
GRCh38: 22:28711907-28711907
20 KRAS NM_004985.5(KRAS):c.35G>C (p.Gly12Ala) SNV Pathogenic
Pathogenic
Pathogenic
45122 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
21 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg) SNV Pathogenic
Likely Pathogenic
45466 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
22 PIK3CA NM_006218.4(PIK3CA):c.1636C>A (p.Gln546Lys) SNV Pathogenic
13657 rs121913286 GRCh37: 3:178936094-178936094
GRCh38: 3:179218306-179218306
23 BRCA1 NM_007294.3:c.(?_-233)_(441+1_442-1)del DEL Pathogenic
634652 GRCh37:
GRCh38:
24 BRCA1 NM_007294.3:c.(?_-233)_(5074+1_5075-1)del DEL Pathogenic
634653 GRCh37:
GRCh38:
25 RAD51C NC_000017.11:g.58705436_58742073del DEL Pathogenic
634658 GRCh37:
GRCh38: 17:58705436-58742073
26 BRCA2 NM_000059.4(BRCA2):c.2399dup (p.Gly800_Asn801insTer) DUP Pathogenic
266696 rs886040423 GRCh37: 13:32910889-32910890
GRCh38: 13:32336752-32336753
27 BRCA2 NM_000059.4(BRCA2):c.5338del (p.Glu1780fs) DEL Pathogenic
634659 rs1566232230 GRCh37: 13:32913830-32913830
GRCh38: 13:32339693-32339693
28 TP53 NM_000546.6(TP53):c.310del (p.Gln104fs) DEL Pathogenic
634663 rs1567555939 GRCh37: 17:7579377-7579377
GRCh38: 17:7676059-7676059
29 TP53 NM_000546.6(TP53):c.371dup (p.Cys124fs) DUP Pathogenic
634664 rs1267047192 GRCh37: 17:7579315-7579316
GRCh38: 17:7675997-7675998
30 TP53 NM_000546.6(TP53):c.153dup (p.Gln52fs) DUP Pathogenic
634665 rs1567556914 GRCh37: 17:7579533-7579534
GRCh38: 17:7676215-7676216
31 TP53 NM_000546.6(TP53):c.460_463del (p.Gly154fs) DEL Pathogenic
634666 rs1567553658 GRCh37: 17:7578467-7578470
GRCh38: 17:7675149-7675152
32 TP53 NM_000546.6(TP53):c.439del (p.Val147fs) DEL Pathogenic
634668 rs1567553924 GRCh37: 17:7578491-7578491
GRCh38: 17:7675173-7675173
33 TP53 NM_000546.6(TP53):c.415A>T (p.Lys139Ter) SNV Pathogenic
634669 rs1212996409 GRCh37: 17:7578515-7578515
GRCh38: 17:7675197-7675197
34 TP53 NM_000546.6(TP53):c.193A>T (p.Arg65Ter) SNV Pathogenic
634670 rs1555526721 GRCh37: 17:7579494-7579494
GRCh38: 17:7676176-7676176
35 TP53 NM_000546.6(TP53):c.361_371del (p.Ser121fs) DEL Pathogenic
634671 rs1567555504 GRCh37: 17:7579316-7579326
GRCh38: 17:7675998-7676008
36 TP53 NM_000546.6(TP53):c.595G>T (p.Gly199Ter) SNV Pathogenic
634672 rs1567551821 GRCh37: 17:7578254-7578254
GRCh38: 17:7674936-7674936
37 TP53 NM_000546.6(TP53):c.298del (p.Gln100fs) DEL Pathogenic
634674 rs1567556006 GRCh37: 17:7579389-7579389
GRCh38: 17:7676071-7676071
38 TP53 NM_000546.6(TP53):c.582del (p.Ile195fs) DEL Pathogenic
634675 rs1567552031 GRCh37: 17:7578267-7578267
GRCh38: 17:7674949-7674949
39 TP53 NM_000546.6(TP53):c.1014_1015insT (p.Glu339Ter) INSERT Pathogenic
634676 rs1567542146 GRCh37: 17:7574012-7574013
GRCh38: 17:7670694-7670695
40 TP53 NM_000546.6(TP53):c.533_540del (p.His178fs) DEL Pathogenic
634677 rs1567552637 GRCh37: 17:7578390-7578397
GRCh38: 17:7675072-7675079
41 TP53 NM_000546.6(TP53):c.155_158dup (p.Trp53Ter) DUP Pathogenic
634678 rs1195793509 GRCh37: 17:7579528-7579529
GRCh38: 17:7676210-7676211
42 TP53 NM_000546.6(TP53):c.675del (p.Gly226fs) DEL Pathogenic
634679 rs1567550076 GRCh37: 17:7577606-7577606
GRCh38: 17:7674288-7674288
43 TP53 NM_000546.6(TP53):c.647_651dup (p.Val218fs) DUP Pathogenic
634681 rs1567551279 GRCh37: 17:7578197-7578198
GRCh38: 17:7674879-7674880
44 TP53 NM_000546.6(TP53):c.680del (p.Ser227fs) DEL Pathogenic
634685 rs1567550018 GRCh37: 17:7577601-7577601
GRCh38: 17:7674283-7674283
45 TP53 NM_000546.6(TP53):c.247del (p.Ala83fs) DEL Pathogenic
634686 rs867725248 GRCh37: 17:7579440-7579440
GRCh38: 17:7676122-7676122
46 TP53 NM_000546.6(TP53):c.538G>T (p.Glu180Ter) SNV Pathogenic
634687 rs879253911 GRCh37: 17:7578392-7578392
GRCh38: 17:7675074-7675074
47 TP53 NM_000546.6(TP53):c.273G>A (p.Trp91Ter) SNV Pathogenic
233650 rs876660548 GRCh37: 17:7579414-7579414
GRCh38: 17:7676096-7676096
48 TP53 NM_000546.6(TP53):c.278del (p.Leu93fs) DEL Pathogenic
634689 rs1567556114 GRCh37: 17:7579409-7579409
GRCh38: 17:7676091-7676091
49 TP53 NM_000546.6(TP53):c.454_466del (p.Pro152fs) DEL Pathogenic
231540 rs876659215 GRCh37: 17:7578464-7578476
GRCh38: 17:7675146-7675158
50 TP53 NM_000546.6(TP53):c.176del (p.Gly59fs) DEL Pathogenic
634691 rs1567556784 GRCh37: 17:7579511-7579511
GRCh38: 17:7676193-7676193

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer:

73
# Symbol AA change Variation ID SNP ID
1 BRCA1 p.Cys61Gly VAR_007757 rs28897672
2 BRCA1 p.Cys1697Arg VAR_020702 rs80356993
3 BRCA1 p.Arg1699Trp VAR_075666 rs55770810
4 CTNNB1 p.Ser37Cys VAR_017625 rs121913403
5 CTNNB1 p.Thr41Ile VAR_017630 rs121913413
6 OPCML p.Pro95Arg VAR_055421 rs137852691
7 PIK3CA p.His1047Arg VAR_026192 rs121913279

Cosmic variations for Ovarian Cancer:

8 (show top 50) (show all 5226)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149326136 ZFHX3 ovary,NS,carcinoma,serous carcinoma c.794A>C p.D265A 16:72959352-72959352 21
2 COSM102045176 ZFHX3 ovary,NS,carcinoma,serous carcinoma c.-23-8387A>C p.? 16:72959352-72959352 21
3 COSM87294257 ZFHX3 ovary,NS,carcinoma,serous carcinoma c.794A>C p.D265A 16:72959352-72959352 21
4 COSM89896720 YES1 ovary,NS,carcinoma,serous carcinoma c.194C>T p.S65F 18:756634-756634 21
5 COSM152022294 YES1 ovary,NS,carcinoma,serous carcinoma c.194C>T p.S65F 18:756634-756634 21
6 COSM136838222 YES1 ovary,NS,carcinoma,serous carcinoma c.209C>T p.S70F 18:756634-756634 21
7 COSM97252460 XRCC2 ovary,NS,carcinoma,serous carcinoma c.121G>C p.G41R 7:152660701-152660701 21
8 COSM104882236 XPO1 ovary,NS,carcinoma,serous carcinoma c.1072T>C p.S358P 2:61494067-61494067 21
9 COSM101976500 XPO1 ovary,NS,carcinoma,serous carcinoma c.1072T>C p.S358P 2:61494067-61494067 21
10 COSM104235731 XPO1 ovary,NS,carcinoma,serous carcinoma c.1072T>C p.S358P 2:61494067-61494067 21
11 COSM113473071 WT1 ovary,NS,carcinoma,serous carcinoma c.1480G>A p.D494N 11:32389123-32389123 21
12 COSM149726304 WT1 ovary,NS,carcinoma,serous carcinoma c.1489G>A p.D497N 11:32389123-32389123 21
13 COSM147411197 WT1 ovary,NS,carcinoma,serous carcinoma c.1429G>A p.D477N 11:32389123-32389123 21
14 COSM100768728 WT1 ovary,NS,carcinoma,serous carcinoma c.844G>A p.D282N 11:32389123-32389123 21
15 COSM148577188 WT1 ovary,NS,carcinoma,serous carcinoma c.1480G>A p.D494N 11:32389123-32389123 21
16 COSM111527104 WT1 ovary,NS,carcinoma,serous carcinoma c.1429G>A p.D477N 11:32389123-32389123 21
17 COSM91369381 WT1 ovary,NS,carcinoma,serous carcinoma c.1489G>A p.D497N 11:32389123-32389123 21
18 COSM130508498 WT1 ovary,NS,carcinoma,serous carcinoma c.802G>A p.D268N 11:32389123-32389123 21
19 COSM109966207 WNK2 ovary,NS,carcinoma,serous carcinoma c.-3489G>T p.? 9:93239962-93239962 21
20 COSM99859094 WNK2 ovary,NS,carcinoma,serous carcinoma c.1528G>T p.V510L 9:93239962-93239962 21
21 COSM85278903 WNK2 ovary,NS,carcinoma,serous carcinoma c.1528G>T p.V510L 9:93239962-93239962 21
22 COSM90881193 WNK1 ovary,NS,carcinoma,serous carcinoma c.2829C>T p.Y943= 12:880028-880028 21
23 COSM128157409 WNK1 ovary,NS,carcinoma,serous carcinoma c.4068C>T p.Y1356= 12:880028-880028 21
24 COSM92016496 WNK1 ovary,NS,carcinoma,serous carcinoma c.3868-1664C>T p.? 12:880028-880028 21
25 COSM130229064 WNK1 ovary,NS,carcinoma,serous carcinoma c.3613-693C>T p.? 12:880028-880028 21
26 COSM132340086 WNK1 ovary,NS,carcinoma,serous carcinoma c.2371-1664C>T p.? 12:880028-880028 21
27 COSM88290578 VHL ovary,NS,carcinoma,serous carcinoma c.430G>A p.G144R 3:10146603-10146603 21
28 COSM90650853 VHL ovary,NS,carcinoma,serous carcinoma c.341-3184G>A p.? 3:10146603-10146603 21
29 COSM97004628 TTN ovary,NS,carcinoma,serous carcinoma c.32594G>C p.R10865T 2:178592591-178592591 21
30 COSM140759517 TTN ovary,NS,carcinoma,serous carcinoma c.76537G>A p.D25513N 2:178569595-178569595 21
31 COSM139644366 TTN ovary,NS,carcinoma,serous carcinoma c.54491G>C p.R18164T 2:178592591-178592591 21
32 COSM91801968 TTN ovary,NS,carcinoma,serous carcinoma c.68833G>A p.D22945N 2:178569595-178569595 21
33 COSM114105946 TTN ovary,NS,carcinoma,serous carcinoma c.32219G>C p.R10740T 2:178592591-178592591 21
34 COSM143495378 TTN ovary,NS,carcinoma,serous carcinoma c.71614G>A p.D23872N 2:178569595-178569595 21
35 COSM139555826 TTN ovary,NS,carcinoma,serous carcinoma c.71614G>A p.D23872N 2:178569595-178569595 21
36 COSM96897173 TTN ovary,NS,carcinoma,serous carcinoma c.49717G>A p.D16573N 2:178569595-178569595 21
37 COSM143582438 TTN ovary,NS,carcinoma,serous carcinoma c.54491G>C p.R18164T 2:178592591-178592591 21
38 COSM90006909 TTN ovary,NS,carcinoma,serous carcinoma c.32795G>C p.R10932T 2:178592591-178592591 21
39 COSM114021618 TTN ovary,NS,carcinoma,serous carcinoma c.49342G>A p.D16448N 2:178569595-178569595 21
40 COSM140848663 TTN ovary,NS,carcinoma,serous carcinoma c.59414G>C p.R19805T 2:178592591-178592591 21
41 COSM91904285 TTN ovary,NS,carcinoma,serous carcinoma c.51710G>C p.R17237T 2:178592591-178592591 21
42 COSM89902825 TTN ovary,NS,carcinoma,serous carcinoma c.49918G>A p.D16640N 2:178569595-178569595 21
43 COSM102619114 TSC2 ovary,NS,carcinoma,serous carcinoma c.1217G>A p.R406K 16:2061968-2061968 21
44 COSM150355623 TSC2 ovary,NS,carcinoma,serous carcinoma c.1217G>A p.R406K 16:2061968-2061968 21
45 COSM150314868 TSC2 ovary,NS,carcinoma,serous carcinoma c.1217G>A p.R406K 16:2061968-2061968 21
46 COSM148982539 TSC2 ovary,NS,carcinoma,serous carcinoma c.1217G>A p.R406K 16:2061968-2061968 21
47 COSM150365158 TSC2 ovary,NS,carcinoma,serous carcinoma c.1361+1G>A p.? 16:2062601-2062601 21
48 COSM151371209 TSC2 ovary,NS,carcinoma,serous carcinoma c.1217G>A p.R406K 16:2061968-2061968 21
49 COSM151753264 TSC2 ovary,NS,carcinoma,serous carcinoma c.272C>T p.P91L 16:2053388-2053388 21
50 COSM90415366 TSC2 ovary,NS,carcinoma,serous carcinoma c.272C>T p.P91L 16:2053388-2053388 21

Copy number variations for Ovarian Cancer from CNVD:

6 (show top 50) (show all 8010)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13413 1 1 23549970 Deletion AADACL3 Ovarian cancer
2 13414 1 1 23549970 Deletion AADACL4 Ovarian cancer
3 13415 1 1 23549970 Deletion ACAP3 Ovarian cancer
4 13416 1 1 23549970 Deletion ACOT7 Ovarian cancer
5 13417 1 1 23549970 Deletion ACTL8 Ovarian cancer
6 13418 1 1 23549970 Deletion ACTRT2 Ovarian cancer
7 13419 1 1 23549970 Deletion AGMAT Ovarian cancer
8 13420 1 1 23549970 Deletion AGRN Ovarian cancer
9 13421 1 1 23549970 Deletion AGTRAP Ovarian cancer
10 13422 1 1 23549970 Deletion AJAP1 Ovarian cancer
11 13423 1 1 23549970 Deletion AKR7A2 Ovarian cancer
12 13424 1 1 23549970 Deletion AKR7A3 Ovarian cancer
13 13425 1 1 23549970 Deletion AKR7L Ovarian cancer
14 13426 1 1 23549970 Deletion ALDH4A1 Ovarian cancer
15 13427 1 1 23549970 Deletion ALPL Ovarian cancer
16 13428 1 1 23549970 Deletion ANGPTL7 Ovarian cancer
17 13429 1 1 23549970 Deletion CENPS Ovarian cancer
18 13430 1 1 23549970 Deletion ARHGEF10L Ovarian cancer
19 13431 1 1 23549970 Deletion ARHGEF16 Ovarian cancer
20 13432 1 1 23549970 Deletion ARHGEF19 Ovarian cancer
21 13433 1 1 23549970 Deletion ATAD3A Ovarian cancer
22 13434 1 1 23549970 Deletion ATAD3B Ovarian cancer
23 13435 1 1 23549970 Deletion ATAD3C Ovarian cancer
24 13436 1 1 23549970 Deletion ATP13A2 Ovarian cancer
25 13437 1 1 23549970 Deletion AURKAIP1 Ovarian cancer
26 13438 1 1 23549970 Deletion B3GALT6 Ovarian cancer
27 13439 1 1 23549970 Deletion C1QA Ovarian cancer
28 13440 1 1 23549970 Deletion C1QB Ovarian cancer
29 13441 1 1 23549970 Deletion C1QC Ovarian cancer
30 13442 1 1 23549970 Deletion TMEM51-AS1 Ovarian cancer
31 13443 1 1 23549970 Deletion C1orf127 Ovarian cancer
32 13444 1 1 23549970 Deletion SZRD1 Ovarian cancer
33 13445 1 1 23549970 Deletion MICOS10 Ovarian cancer
34 13446 1 1 23549970 Deletion CFAP107 Ovarian cancer
35 13447 1 1 23549970 Deletion C1orf159 Ovarian cancer
36 13448 1 1 23549970 Deletion PERM1 Ovarian cancer
37 13449 1 1 23549970 Deletion C1orf174 Ovarian cancer
38 13450 1 1 23549970 Deletion DRAXIN Ovarian cancer
39 13451 1 1 23549970 Deletion PIK3CD-AS1 Ovarian cancer
40 13452 1 1 23549970 Deletion SRARP Ovarian cancer
41 13453 1 1 23549970 Deletion TMEM240 Ovarian cancer
42 13454 1 1 23549970 Deletion FAAP20 Ovarian cancer
43 13455 1 1 23549970 Deletion CPLANE2 Ovarian cancer
44 13456 1 1 23549970 Deletion PRXL2B Ovarian cancer
45 13457 1 1 23549970 Deletion CA6 Ovarian cancer
46 13458 1 1 23549970 Deletion CALML6 Ovarian cancer
47 13459 1 1 23549970 Deletion CAMK2N1 Ovarian cancer
48 13460 1 1 23549970 Deletion CAMTA1 Ovarian cancer
49 13461 1 1 23549970 Deletion CAPZB Ovarian cancer
50 13462 1 1 23549970 Deletion CASP9 Ovarian cancer

Expression for Ovarian Cancer

Search GEO for disease gene expression data for Ovarian Cancer.

Pathways for Ovarian Cancer

Pathways related to Ovarian Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.15 AKT1 BRCA1 BRIP1 CDKN2A CTNNB1 ERBB2
2
Show member pathways
13.91 AKT1 BRAF BRCA1 CDH1 CDKN2A CTNNB1
3 13.85 AKT1 BRAF CDH1 CTNNB1 ERBB2 KRAS
4
Show member pathways
13.68 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
5
Show member pathways
13.63 AKT1 BRAF BRCA1 CDH1 ERBB2 KRAS
6
Show member pathways
13.51 TP53 PTEN PIK3CA MSH6 MAP3K1 KRAS
7
Show member pathways
13.48 PTEN PIK3CA MAP3K1 KRAS CTNNB1 BRAF
8
Show member pathways
13.45 PTEN PIK3CA KRAS ERBB2 CTNNB1 BRAF
9
Show member pathways
13.31 TP53 RAD51D RAD51C MSH6 MSH2 BRIP1
10
Show member pathways
13.06 TP53 RAD51D PTEN MSH2 CDKN2A BRIP1
11
Show member pathways
13.04 TP53 PTEN PIK3CA KRAS BRCA1 AKT1
12
Show member pathways
13.02 PTEN KRAS CTNNB1 CDH1 BRAF AKT1
13
Show member pathways
13.01 TP53 PTEN PIK3CA MAP3K1 CDKN2A AKT1
14
Show member pathways
13 TP53 MSH6 MSH2 MAP3K1 KRAS BRIP1
15
Show member pathways
12.97 PTEN PIK3CA MAP3K1 KRAS ERBB2 BRAF
16
Show member pathways
12.95 TP53 PIK3CA MAP3K1 KRAS BRAF AKT1
17
Show member pathways
12.93 PTEN PIK3CA KRAS BRAF AKT1
18 12.93 PIK3CA KRAS ERBB2 CTNNB1 BRAF AKT1
19
Show member pathways
12.91 PIK3CA KRAS CTNNB1 BRAF AKT1
20
Show member pathways
12.85 TP53 KRAS CTNNB1 CDH1 AKT1
21
Show member pathways
12.85 BRCA1 BRCA2 BRIP1 MSH2 MSH6 RAD51C
22 12.79 AKT1 BRCA1 CDH1 CDKN2A CTNNB1 MAP3K1
23
Show member pathways
12.75 TP53 CTNNB1 CDKN2A CDH1 AKT1
24
Show member pathways
12.75 MAP3K1 KRAS CDKN2A BRAF AKT1
25
Show member pathways
12.75 TP53 MAP3K1 KRAS BRAF AKT1
26
Show member pathways
12.74 BRCA1 BRCA2 BRIP1 MSH2 MSH6 RAD51C
27
Show member pathways
12.72 TP53 MSH6 MSH2 MAP3K1 BRCA2 BRCA1
28
Show member pathways
12.69 AKT1 CTNNB1 ERBB2 KRAS MSH2 PIK3CA
29 12.61 TP53 MSH6 MSH2 CDKN2A BRIP1 BRCA2
30
Show member pathways
12.55 TP53 PIK3CA KRAS ERBB2 CTNNB1 AKT1
31 12.53 AKT1 CDH1 CTNNB1 MAP3K1 TP53
32 12.51 TP53 MAP3K1 KRAS BRAF AKT1
33
Show member pathways
12.51 AKT1 BRAF BRCA1 CTNNB1 KRAS MAP3K1
34
Show member pathways
12.51 TP53 PIK3CA MAP3K1 KRAS ERBB2 CTNNB1
35
Show member pathways
12.5 PIK3CA MAP3K1 KRAS ERBB2 CTNNB1 CDH1
36
Show member pathways
12.49 PIK3CA MAP3K1 KRAS AKT1
37
Show member pathways
12.49 TP53 PTEN PIK3CA MAP3K1 ERBB2 CTNNB1
38
Show member pathways
12.46 BRCA1 BRCA2 BRIP1 RAD51C RAD51D
39
Show member pathways
12.42 AKT1 MAP3K1 PIK3CA PTEN
40
Show member pathways
12.4 PTEN PIK3CA KRAS AKT1
41
Show member pathways
12.4 PIK3CA KRAS CTNNB1 AKT1
42 12.4 PTEN PIK3CA ERBB2 CTNNB1 BRAF AKT1
43
Show member pathways
12.39 TP53 PIK3CA MAP3K1 AKT1
44
Show member pathways
12.39 PTEN PIK3CA MAP3K1 BRAF AKT1
45
Show member pathways
12.39 AKT1 BRAF BRCA1 BRCA2 CTNNB1 ERBB2
46
Show member pathways
12.35 TP53 PTEN PIK3CA AKT1
47
Show member pathways
12.34 PIK3CA MAP3K1 CTNNB1 AKT1
48
Show member pathways
12.32 TP53 PTEN PIK3CA KRAS ERBB2 BRAF
49
Show member pathways
12.3 TP53 PTEN BRCA1 AKT1
50
Show member pathways
12.29 PIK3CA MAP3K1 KRAS AKT1

GO Terms for Ovarian Cancer

Cellular components related to Ovarian Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear ubiquitin ligase complex GO:0000152 9.62 BRCA2 BRCA1
2 BRCA1-B complex GO:0070532 9.56 BRIP1 BRCA1
3 Rad51B-Rad51C-Rad51D-XRCC2 complex GO:0033063 9.46 RAD51D RAD51C
4 replication fork GO:0005657 9.43 TP53 RAD51D RAD51C
5 MutSalpha complex GO:0032301 8.92 MSH6 MSH2

Biological processes related to Ovarian Cancer according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 10.25 MAP3K1 KRAS CTNNB1 BRAF
2 negative regulation of gene expression GO:0010629 10.25 AKT1 BRIP1 CTNNB1 PIK3CA PRKN TP53
3 phosphorylation GO:0016310 10.21 PIK3CA MAP3K1 ERBB2 CDKN2A BRAF AKT1
4 negative regulation of neuron apoptotic process GO:0043524 10.19 PRKN PIK3CA MSH2 KRAS BRAF
5 double-strand break repair via homologous recombination GO:0000724 10.18 RAD51D RAD51C BRCA2 BRCA1
6 regulation of cell cycle GO:0051726 10.18 TP53 RAD51D PTEN MSH2 CDKN2A BRCA1
7 DNA repair GO:0006281 10.13 BRCA1 BRCA2 BRIP1 MSH2 MSH6 RAD51C
8 nucleotide-excision repair GO:0006289 10.11 TP53 BRIP1 BRCA2
9 regulation of protein stability GO:0031647 10.11 PTEN PRKN KRAS CDKN2A
10 T cell differentiation in thymus GO:0033077 10.1 BRAF CTNNB1 TP53
11 cellular response to ionizing radiation GO:0071479 10.1 TP53 BRCA2 BRCA1
12 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 10.07 TP53 MSH2 BRCA2
13 negative regulation of reactive oxygen species metabolic process GO:2000378 10.02 TP53 PRKN BRCA1
14 determination of adult lifespan GO:0008340 10.01 TP53 MSH6 MSH2
15 phosphatidylinositol 3-kinase signaling GO:0014065 10.01 PTEN PIK3CA ERBB2 AKT1
16 response to X-ray GO:0010165 10 TP53 MSH2 BRCA2
17 positive regulation of helicase activity GO:0051096 9.96 MSH6 MSH2
18 DNA recombination GO:0006310 9.96 BRCA1 BRCA2 RAD51C RAD51D
19 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.93 BRCA1 BRCA2 MSH2 MSH6
20 somatic recombination of immunoglobulin gene segments GO:0016447 9.91 MSH6 MSH2
21 telomere maintenance via recombination GO:0000722 9.91 RAD51D RAD51C BRCA2
22 cell population proliferation GO:0008283 9.91 TP53 PTEN KRAS CTNNB1 BRCA2 AKT1
23 chromosome organization GO:0051276 9.88 TP53 RAD51D BRCA2
24 double-strand break repair GO:0006302 9.85 TP53 MSH2 BRIP1 BRCA2 BRCA1
25 DNA metabolic process GO:0006259 9.82 RAD51D RAD51C BRIP1
26 chordate embryonic development GO:0043009 9.82 BRCA2 BRCA1
27 negative regulation of immature T cell proliferation in thymus GO:0033088 9.81 ERBB2 CDKN2A
28 maintenance of DNA repeat elements GO:0043570 9.79 MSH6 MSH2
29 cellular response to decreased oxygen levels GO:0036294 9.77 AKT1 PTEN
30 cellular response to indole-3-methanol GO:0071681 9.73 CTNNB1 CDH1 BRCA1
31 cellular response to DNA damage stimulus GO:0006974 9.65 BRCA1 BRCA2 BRIP1 MSH2 MSH6 RAD51C
32 positive regulation of gene expression GO:0010628 9.53 TP53 PRKN KRAS ERBB2 CTNNB1 CDKN2A

Molecular functions related to Ovarian Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.5 TP53 PTEN PRKN KRAS ERBB2 CDH1
2 ATP binding GO:0005524 10.43 RAD51D RAD51C PIK3CA MSH6 MSH2 MAP3K1
3 protein kinase binding GO:0019901 10.22 TP53 PTEN PRKN MSH2 MAP3K1 CTNNB1
4 enzyme binding GO:0019899 10.16 AKT1 BRCA1 CTNNB1 MSH2 MSH6 PRKN
5 kinase activity GO:0016301 10.06 PIK3CA MAP3K1 ERBB2 CDKN2A BRAF AKT1
6 ATP-dependent activity, acting on DNA GO:0008094 9.95 MSH2 MSH6 RAD51D
7 disordered domain specific binding GO:0097718 9.91 TP53 CTNNB1 CDKN2A
8 guanine/thymine mispair binding GO:0032137 9.8 MSH6 MSH2
9 ATP-dependent DNA damage sensor activity GO:0140664 9.76 RAD51D RAD51C MSH6 MSH2
10 single guanine insertion binding GO:0032142 9.71 MSH2 MSH6
11 nucleotide binding GO:0000166 9.7 RAD51D RAD51C PIK3CA MSH6 MSH2 MAP3K1
12 single thymine insertion binding GO:0032143 9.67 MSH6 MSH2
13 four-way junction DNA binding GO:0000400 9.23 RAD51D RAD51C MSH6 MSH2

Sources for Ovarian Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....